@michael-robersmd.bsky.social
neuroimmunology/ multiple sclerosis specialist at Barrow Neurological Institute. Neuroscience educator at Creighton-PHX. Health equity and clinical researcher. Views are my own and do not represent individual medical advice or the views of my employers.
Another Teaching case published by the dedicated trainees at Barrow Neurological Institute. Congratulations to Dr. Victoria Lorah Barker, the first author. I like the format of the interactive cases here
Interactive case# 61: interactn.or
Traditional written publication:
lnkd.in/gM_AYcic
Interactive case# 61: interactn.or
Traditional written publication:
lnkd.in/gM_AYcic
Home - interACTN
interactn.org
September 17, 2026 at 8:00 PM
Another Teaching case published by the dedicated trainees at Barrow Neurological Institute. Congratulations to Dr. Victoria Lorah Barker, the first author. I like the format of the interactive cases here
Interactive case# 61: interactn.or
Traditional written publication:
lnkd.in/gM_AYcic
Interactive case# 61: interactn.or
Traditional written publication:
lnkd.in/gM_AYcic
Congratulations to Barrow Neurological Institute neuroimmunology fellow Maria A Garcia-Dominguez finishing strong before her graduation next month. in just a one year fellowship she presented at ACTRIMS, AAN and now #CMSC26. looking forward to watching her bright future.
May 29, 2026 at 2:39 PM
Congratulations to Barrow Neurological Institute neuroimmunology fellow Maria A Garcia-Dominguez finishing strong before her graduation next month. in just a one year fellowship she presented at ACTRIMS, AAN and now #CMSC26. looking forward to watching her bright future.
last day of #CMSC26 I'm listening to the biomarkers session. lots of data presented before this, but below is the great summary slide by Ahmed Abdelhak binging an hour + into my new visualization.
May 29, 2026 at 2:21 PM
last day of #CMSC26 I'm listening to the biomarkers session. lots of data presented before this, but below is the great summary slide by Ahmed Abdelhak binging an hour + into my new visualization.
Had a great #AANAM2026. while I was not involved in most of these, I have to brag about Creighton University School of Medicine students Chloe Cohan and Mawj Alzakar, both of whom had abstracts, and BNI resident Vishnu Dantu and fellow Maria Garcia-Dominguez who each had neuroimmunology abstracts.
April 22, 2026 at 11:52 PM
Had a great #AANAM2026. while I was not involved in most of these, I have to brag about Creighton University School of Medicine students Chloe Cohan and Mawj Alzakar, both of whom had abstracts, and BNI resident Vishnu Dantu and fellow Maria Garcia-Dominguez who each had neuroimmunology abstracts.
#AANAM2026 non-inferiority study of fenebrutinib vs ocrelizumab in PPMS. fenebrutinib is non-inferior to ocrelizumab BUT the inactive PPMS population differs from the original ORATORIO trial, so non-inferior to what? I don't have great confidence in ocrelizumab's efficacy in this population.
April 22, 2026 at 7:11 PM
#AANAM2026 non-inferiority study of fenebrutinib vs ocrelizumab in PPMS. fenebrutinib is non-inferior to ocrelizumab BUT the inactive PPMS population differs from the original ORATORIO trial, so non-inferior to what? I don't have great confidence in ocrelizumab's efficacy in this population.
#AANAM2026 ocrelizumab vs placebo in older and more disabled PPMS patients: delayed disability progression in EDSS and 9 hole peg. Better in younger, Active MS, and More disabled subgroups.
April 22, 2026 at 6:33 PM
#AANAM2026 ocrelizumab vs placebo in older and more disabled PPMS patients: delayed disability progression in EDSS and 9 hole peg. Better in younger, Active MS, and More disabled subgroups.
Exciting results in the clinical trial Plenary at #AANAM2026.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
April 21, 2026 at 4:08 PM
Exciting results in the clinical trial Plenary at #AANAM2026.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
Exciting results in the clinical trial Plenary at #AANAM2026.
First, phase 2 trial on neuro protection in acute optic neuritis. Privosegtor 3mg/kg dosed within 12 days of symptoms WITH concurrent IVSM showed benefit in low contrast visual acuity and OCT. notably aqp4+ excluded.
First, phase 2 trial on neuro protection in acute optic neuritis. Privosegtor 3mg/kg dosed within 12 days of symptoms WITH concurrent IVSM showed benefit in low contrast visual acuity and OCT. notably aqp4+ excluded.
April 21, 2026 at 4:03 PM
Exciting results in the clinical trial Plenary at #AANAM2026.
First, phase 2 trial on neuro protection in acute optic neuritis. Privosegtor 3mg/kg dosed within 12 days of symptoms WITH concurrent IVSM showed benefit in low contrast visual acuity and OCT. notably aqp4+ excluded.
First, phase 2 trial on neuro protection in acute optic neuritis. Privosegtor 3mg/kg dosed within 12 days of symptoms WITH concurrent IVSM showed benefit in low contrast visual acuity and OCT. notably aqp4+ excluded.
#AAN2026 #neurosky
Today's presidential plenary session. Consistent examples of the importance of basic science translation in neurology. From understanding the role of nuclear porins in sporadic ALS studying childhood genetic disorders. The future of translational neurologic science is bright!
Today's presidential plenary session. Consistent examples of the importance of basic science translation in neurology. From understanding the role of nuclear porins in sporadic ALS studying childhood genetic disorders. The future of translational neurologic science is bright!
April 19, 2026 at 4:27 PM
#AANAM #neurosky On future physician shortages: US physician workforce is expected to be at only 88% of need in 2038, Neurology is expected to be fully staffed at 104%. The room of neurologists disagreed.
Do we have enough neurologists in the training pathway?
bhw.hrsa.gov/sites/defaul...
Do we have enough neurologists in the training pathway?
bhw.hrsa.gov/sites/defaul...
bhw.hrsa.gov
April 19, 2026 at 1:16 PM
#AANAM #neurosky On future physician shortages: US physician workforce is expected to be at only 88% of need in 2038, Neurology is expected to be fully staffed at 104%. The room of neurologists disagreed.
Do we have enough neurologists in the training pathway?
bhw.hrsa.gov/sites/defaul...
Do we have enough neurologists in the training pathway?
bhw.hrsa.gov/sites/defaul...
Newest publication out from several of the outstanding trainees at Barrow Neurology: necrotizing granulomatous encephalitis after endovascular therapy. Congratulations Drs Kaneko, Khanna, and Malaty!
doi.org/10.1212/WNL....
doi.org/10.1212/WNL....
Teaching NeuroImage: Necrotizing Granulomatous Encephalitis in a Patient After a Pericallosal Aneurysm Stent-Assisted Coil | Neurology
doi.org
December 4, 2025 at 11:19 PM
Newest publication out from several of the outstanding trainees at Barrow Neurology: necrotizing granulomatous encephalitis after endovascular therapy. Congratulations Drs Kaneko, Khanna, and Malaty!
doi.org/10.1212/WNL....
doi.org/10.1212/WNL....
Day 3 of #ECTRIMS2025
extension results for ravulizumab in NMO disease (AQP4+). 0 relapses in 105 patient years! absolutely incredible efficacy!
extension results for ravulizumab in NMO disease (AQP4+). 0 relapses in 105 patient years! absolutely incredible efficacy!
September 26, 2025 at 7:22 AM
Day 3 of #ECTRIMS2025
extension results for ravulizumab in NMO disease (AQP4+). 0 relapses in 105 patient years! absolutely incredible efficacy!
extension results for ravulizumab in NMO disease (AQP4+). 0 relapses in 105 patient years! absolutely incredible efficacy!
Our abstract on High Efficacy Therapy Use by race/ethnicity. We found that while non-White individuals had higher rates of HET use, the association disappeared when adjusted for disability implying that clinical factors drive prescription patterns. # ECTRIMS2025
September 25, 2025 at 6:12 PM
Our abstract on High Efficacy Therapy Use by race/ethnicity. We found that while non-White individuals had higher rates of HET use, the association disappeared when adjusted for disability implying that clinical factors drive prescription patterns. # ECTRIMS2025
#ECTRIMS2025. only 50% of MS patients are up to date vaccines. Inactivated vaccines are NOT associated with relapses and are safe to take in MS. Vaccines are a safe way to reduce infection risk on DMTs. live vaccines may be contraindicated on tx but Can be given 4 weeks before DMT initiation.
September 25, 2025 at 12:53 PM
#ECTRIMS2025. only 50% of MS patients are up to date vaccines. Inactivated vaccines are NOT associated with relapses and are safe to take in MS. Vaccines are a safe way to reduce infection risk on DMTs. live vaccines may be contraindicated on tx but Can be given 4 weeks before DMT initiation.
Imaging in chronic inflammation session at #ECTRIMS2025 was quite interesting. Several abstracts looking at associations between choroid plexus size and PIRA and chronic active MS lesions. A future easily accessible progressive MS biomarker? #multiplesclerosis
September 25, 2025 at 11:40 AM
Imaging in chronic inflammation session at #ECTRIMS2025 was quite interesting. Several abstracts looking at associations between choroid plexus size and PIRA and chronic active MS lesions. A future easily accessible progressive MS biomarker? #multiplesclerosis
eposter up and available at #ECTRIMS2025. HTN awareness is lower in Hispanic people with MS than the general population and lower than a recent predominantly White MS cohort. younger age is associated with worse awareness, but integrated healthcare is associated with better awareness.
September 24, 2025 at 5:18 PM
eposter up and available at #ECTRIMS2025. HTN awareness is lower in Hispanic people with MS than the general population and lower than a recent predominantly White MS cohort. younger age is associated with worse awareness, but integrated healthcare is associated with better awareness.
P113 American Heart Association Blood Pressure Categories Have Stronger Associations with Worsening Disability than other Hypertension Metrics In Multiple Sclerosis.
- AHA stage II HTN may be a better tool than SBP or DBP alone for future MS HTN comorbidity research
Come visit!
- AHA stage II HTN may be a better tool than SBP or DBP alone for future MS HTN comorbidity research
Come visit!
September 24, 2025 at 2:33 PM
P113 American Heart Association Blood Pressure Categories Have Stronger Associations with Worsening Disability than other Hypertension Metrics In Multiple Sclerosis.
- AHA stage II HTN may be a better tool than SBP or DBP alone for future MS HTN comorbidity research
Come visit!
- AHA stage II HTN may be a better tool than SBP or DBP alone for future MS HTN comorbidity research
Come visit!
2025 NMO criteria. Lots of nomenclature updates but the core is still what we already knew...
September 24, 2025 at 1:27 PM
2025 NMO criteria. Lots of nomenclature updates but the core is still what we already knew...
#ECTRIMS2025
Lots of diagnostic updates on day 1! 2024 McDonald criteria re-released in conjunction with the lancet papers last week. Reaffirming most of the major changes and attempting to provide better algorithms. Heads up the online PDF had errors last week. Re-download now if you got it before.
Lots of diagnostic updates on day 1! 2024 McDonald criteria re-released in conjunction with the lancet papers last week. Reaffirming most of the major changes and attempting to provide better algorithms. Heads up the online PDF had errors last week. Re-download now if you got it before.
September 24, 2025 at 1:10 PM
#ECTRIMS2025
Lots of diagnostic updates on day 1! 2024 McDonald criteria re-released in conjunction with the lancet papers last week. Reaffirming most of the major changes and attempting to provide better algorithms. Heads up the online PDF had errors last week. Re-download now if you got it before.
Lots of diagnostic updates on day 1! 2024 McDonald criteria re-released in conjunction with the lancet papers last week. Reaffirming most of the major changes and attempting to provide better algorithms. Heads up the online PDF had errors last week. Re-download now if you got it before.
Looking Forward to a wonderful three days of scientific discussion around improving the care of MS! #ECTRIMS2025
September 24, 2025 at 12:52 PM
Looking Forward to a wonderful three days of scientific discussion around improving the care of MS! #ECTRIMS2025
fear of falling and objectively slower reactive stepping are associated with each other in people with MS, especially in those with a history of falls. Thanks Dan Peterson for inviting me to collaborate. I look forward to working with you in the future. www.sciencedirect.com/science/arti...
Fall history moderates the relationship between concern about falling and reactive stepping performance in people with multiple sclerosis
Reactive balance (quick motoric responses to an external balance challenge) and affective characteristics are linked to falls and negatively impacted …
www.sciencedirect.com
August 13, 2025 at 2:01 PM
fear of falling and objectively slower reactive stepping are associated with each other in people with MS, especially in those with a history of falls. Thanks Dan Peterson for inviting me to collaborate. I look forward to working with you in the future. www.sciencedirect.com/science/arti...
I haven't had a chance to post this, but I had the opportunity to discuss our research on Hypertension Awareness with neurology live at CMSC. check out this short highlight!
Hypertension Awareness Gaps in Patients With Multiple Sclerosis: Michael Robers, MD, MS share.google/wTGUzi2pwaX4...
Hypertension Awareness Gaps in Patients With Multiple Sclerosis: Michael Robers, MD, MS share.google/wTGUzi2pwaX4...
Hypertension Awareness Gaps in Patients With Multiple Sclerosis: Michael Robers, MD, MS
The assistant professor of neurology at Barrow Neurological Institute talked about the lack of public awareness for hypertension among individuals with MS despite many meeting diagnostic criteria. [W...
share.google
August 7, 2025 at 4:51 AM
I haven't had a chance to post this, but I had the opportunity to discuss our research on Hypertension Awareness with neurology live at CMSC. check out this short highlight!
Hypertension Awareness Gaps in Patients With Multiple Sclerosis: Michael Robers, MD, MS share.google/wTGUzi2pwaX4...
Hypertension Awareness Gaps in Patients With Multiple Sclerosis: Michael Robers, MD, MS share.google/wTGUzi2pwaX4...
Nice that Barrow was recognized for neurological care, but I'm especially happy to see our #MultipleSclerosis center recognized as a "stand out specialty".
rankings.newsweek.com/americas-bes...
rankings.newsweek.com/americas-bes...
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
July 24, 2025 at 11:48 PM
Nice that Barrow was recognized for neurological care, but I'm especially happy to see our #MultipleSclerosis center recognized as a "stand out specialty".
rankings.newsweek.com/americas-bes...
rankings.newsweek.com/americas-bes...